Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Lidocaine and Midazolam for NGT Insertion Pain in Children
NCT04571879Phase 3Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine 10% oropharyngeal spray and midazolam in procedural pain and Procedural anxiety (3 arms), sponsored by Hamad Medical Corporation. Primary endpoint: Pain severity rating scale (FLACC) during insertion of NGT. Status: unknown.
02
Drugs
lidocaine 10% oropharyngeal spraymidazolam
03
Conditions
procedural painProcedural anxiety
Beyond the preview
Go deeper on NCT04571879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571879.